# The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

> **NCT02546609** · PHASE2 · COMPLETED · sponsor: **NuSirt Biopharma** · enrollment: 91 (actual)

## Conditions studied

- NAFLD

## Interventions

- **DRUG:** Leu-Met-Sil 0.5
- **DRUG:** Leu-Met-Sil 1.0
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02546609
- **Lead sponsor:** NuSirt Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-19
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-01-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2018-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546609, "The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02546609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*